Analysts say the drug could emerge as a potential competitor to Merck’s blockbuster immunotherapy Keytruda. Keytruda is ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

The FDA’s premarket approval green light spans one pan-cancer ... Finally, the assay can be used with Merck’s Keytruda ...

If, as ivonescimab’s victory over Keytruda suggested, PD-(L ... BioNTech is also exploring combinations with antibody-drug ...

"By 2024, the market is projected to reach a staggering US$597.00bn worldwide. Among these markets, Medical Devices are expected to dominate, with a projected market volume of US$508.00bn by 2024.

More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...

October 2024, saw significant FDA actions and clinical trial updates that shaped cancer ... The combination of neoadjuvant pembrolizumab (Keytruda) combined with chemotherapy, followed by adjuvant ...

The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.

In the trial, patients with non-small-cell lung cancer (NSCLC) were treated with either ivonescimab or the drug that's the ...

FDA approval of tarlatamab (Imdelltra ... patients with glioblastoma treated with the bivalent CAR T-cell therapy also ...

The president-elect has said he’ll let Robert F. Kennedy Jr. “go wild” on healthcare, while many expect a leadership change ...